- Home
- YSXT vs IFRX Comparison
YSXT vs IFRX Comparison
Compare YSXT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSXT
- IFRX
- Stock Information
- Founded
- YSXT 2011
- IFRX 2007
- Country
- YSXT China
- IFRX Germany
- Employees
- YSXT N/A
- IFRX N/A
- Industry
- YSXT Automotive Aftermarket
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- YSXT Consumer Discretionary
- IFRX Health Care
- Exchange
- YSXT Nasdaq
- IFRX Nasdaq
- Market Cap
- YSXT 58.6M
- IFRX 53.5M
- IPO Year
- YSXT 2024
- IFRX 2017
- Fundamental
- Price
- YSXT $2.88
- IFRX $1.32
- Analyst Decision
- YSXT
- IFRX Strong Buy
- Analyst Count
- YSXT 0
- IFRX 5
- Target Price
- YSXT N/A
- IFRX $7.40
- AVG Volume (30 Days)
- YSXT 157.9K
- IFRX 754.8K
- Earning Date
- YSXT 07-31-2025
- IFRX 11-07-2025
- Dividend Yield
- YSXT N/A
- IFRX N/A
- EPS Growth
- YSXT N/A
- IFRX N/A
- EPS
- YSXT 0.18
- IFRX N/A
- Revenue
- YSXT $71,452,736.00
- IFRX $191,224.00
- Revenue This Year
- YSXT N/A
- IFRX N/A
- Revenue Next Year
- YSXT N/A
- IFRX $1,216.24
- P/E Ratio
- YSXT $14.76
- IFRX N/A
- Revenue Growth
- YSXT 22.04
- IFRX 54.36
- 52 Week Low
- YSXT $1.68
- IFRX $0.71
- 52 Week High
- YSXT $9.96
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- YSXT 60.63
- IFRX 48.96
- Support Level
- YSXT $2.35
- IFRX $1.20
- Resistance Level
- YSXT $2.68
- IFRX $1.71
- Average True Range (ATR)
- YSXT 0.21
- IFRX 0.17
- MACD
- YSXT 0.04
- IFRX 0.00
- Stochastic Oscillator
- YSXT 83.10
- IFRX 32.76
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.